The Importance of Guideline-Recommended Biomarker Testing and Multidisciplinary Treatment in Resectable Stage IB-IIIA Non-Small Cell Lung Cancer

Article Type
Changed
Tue, 12/20/2022 - 18:36


In this article, Gerard A. Silvestri, MD, MS, FCCP discusses guideline-recommended testing and multidisciplinary care for resectable non-small cell lung cancer.

 

Read More

Neither the editors of CHEST Physician® nor the Editorial Advisory Board nor the reporting staff contributed to this content.

Sponsor
Developed under the direction and sponsorship of AstraZeneca
Publications
Sponsor
Developed under the direction and sponsorship of AstraZeneca
Sponsor
Developed under the direction and sponsorship of AstraZeneca


In this article, Gerard A. Silvestri, MD, MS, FCCP discusses guideline-recommended testing and multidisciplinary care for resectable non-small cell lung cancer.

 

Read More

Neither the editors of CHEST Physician® nor the Editorial Advisory Board nor the reporting staff contributed to this content.


In this article, Gerard A. Silvestri, MD, MS, FCCP discusses guideline-recommended testing and multidisciplinary care for resectable non-small cell lung cancer.

 

Read More

Neither the editors of CHEST Physician® nor the Editorial Advisory Board nor the reporting staff contributed to this content.

Publications
Publications
Article Type
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
Information from Industry- Sponsored Content
Gate On Date
Wed, 09/29/2021 - 09:30
Un-Gate On Date
Wed, 09/29/2021 - 09:30
Use ProPublica
CFC Schedule Remove Status
Wed, 09/29/2021 - 09:30
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article